DNMT3B and acute lymphoblastic leukemia: In T-ALL, silencing DNMT3B using DNMT3B shRNA reduced cell viability and cell growth, as evidenced by a decrease in the number of cells in the S-phase and an increase in the levels of CDKN1A (p21CIP1), CDKN2B (p15INK4b), CDKN2A (p16INK4a), and CDKN2D (p19INK4d) (140).